|
1 Indications And Usage Tykerb ® Is Indicated In Combination With: • Capecitabine For The Treatment Of Patients With Advanced Or Metastatic Breast Cancer Whose Tumors Overexpress Human Epidermal Growth Factor Receptor 2 (Her2) And Who Have Received Prior Therapy Including An Anthracycline, A Taxane, And Trastuzumab. Limitations Of Use : Patients Should Have Disease Progression On Trastuzumab Prior To Initiation Of Treatment With Tykerb In Combination With Capecitabine. • Letrozole For The Treatment Of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer That Overexpresses The Her2 Receptor For Whom Hormonal Therapy Is Indicated. Tykerb In Combination With An Aromatase Inhibitor Has Not Been Compared To A Trastuzumab-Containing Chemotherapy Regimen For The Treatment Of Metastatic Breast Cancer. Tykerb Is A Kinase Inhibitor Indicated In Combination With: ( 1 ) Capecitabine For The Treatment Of Patients With Advanced Or Metastatic Breast Cancer Whose Tumors Overexpress Human Epidermal Growth Factor Receptor 2 (Her2) And Who Have Received Prior Therapy Including An Anthracycline, A Taxane, And Trastuzumab. Limitations Of Use : Patients Should Have Disease Progression On Trastuzumab Prior To Initiation Of Treatment With Tykerb In Combination With Capecitabine. Letrozole For The Treatment Of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer That Overexpresses The Her2 Receptor For Whom Hormonal Therapy Is Indicated. Tykerb In Combination With An Aromatase Inhibitor Has Not Been Compared To A Trastuzumab-Containing Chemotherapy Regimen For The Treatment Of Metastatic Breast Cancer.
|